Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Panacea Biotec Bail...

    Panacea Biotec Bail out: Piramal, Bain offer Rs 992 crore deal

    GarimaWritten by Garima Published On 2019-04-09T09:45:15+05:30  |  Updated On 22 Dec 2022 3:21 PM IST




    MUMBAI: India Resurgence Fund (IRF) led by Piramal Enterprises and Bain Capital Credit recently said it will invest Rs 992 crore in New Delhi-based pharma player Panacea Biotec which is facing a severe financial crisis.

    According to recent media reports, the funds will be used for one-time settlement with the existing lenders, general working capital and growth requirements of Panacea Biotec

    The joint venture fund has been active in the pharma business and the announcement comes after the February 26 announcement by Panacea about reaching a one-time settlement with the lenders to pay off Rs 864 crore of debt.

    Medical Dialogues had earlier reported that with an objective of clearing its debt, Panacea Biotec moved to sell out its Gurgaon Hospital.

    Also Read: Narayana Hrudayalaya in talks with Panacea Biotech to buy its Gurgaon Hospital??


    As per recent media reports, IRF said that the deal involves an investment of Rs 864 crore into a forthcoming non-convertible debenture issue, and Rs 32 crore towards subscription in share warrants to be allotted on a preferential basis.

    Subject to the exercise of warrants, the fund and its affiliates will collectively own 10.4 per cent of the company on a fully diluted basis, it said.


    The subscription amount represents 25 per cent of the total amount of Rs 128 crore proposed to be raised on issuances of equity shares against warrants as per Sebi rules, it added.





    Fund's managing director Shantanu Nalavadi said Panacea is embarking on a journey to enhance its market position as a strong and research-focused pharma and biotechnology company.

    He further said the fund has invested to work closely with the promoters and management team to drive rapid revenue growth and sustainable profitability improvement.

    "We look forward to leveraging their proven global expertise in restructuring and turn arounds and are certain that our combined efforts will now help accelerate our ambitious growth and profitability targets," Panacea managing director Rajesh Jain said.

    On February 26, Panacea had arrived at a one-time settlement with the lenders and at the extraordinary general meeting held on March 25, the shareholders had allowed the management to raise up to Rs 128 crore via issue of warrants on a preferential basis.

    Panacea Drugs Pvt. Ltd. was set up in the year 1984 and got listed in 1995 as Panacea Biotec Ltd. Panacea Biotec is an Indian research-based pharmaceutical and health management company involved in research, manufacturing, and marketing of pharmaceutical formulations, vaccines, and natural products. It is one of the three largest biotech companies in India.


    Also Read: Plea against patent for pneumonia vaccine filed by Panacea Biotec


    Ajay Piramalbail out dealbainBain Capitalbiotecconvertible debentureIndia Resurgence FundPanaceaPanacea BiotecPanacea subscriptionpharmapharma businesspharma newspharma news indiaPharmaceutical industryPiramalSEBI
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok